Structural analysis of Mycobacterium tuberculosis M13 metalloprotease Zmp1 open states

Wenguang G Liang1, Jordan M Mancl1, Minglei Zhao2

  • 1Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.

Insights

This study reveals the open-state structures of Mycobacterium tuberculosis Zinc metalloprotease 1 (Zmp1), a key enzyme in tuberculosis. These structures explain how Zmp1 binds substrates, offering new avenues for therapeutic interventions against tuberculosis.

Area of Science:

  • Structural biology
  • Biochemistry
  • Microbiology

Background:

  • Mycobacterium tuberculosis Zinc metalloprotease 1 (Zmp1) is a secreted enzyme crucial for tuberculosis pathogenesis.
  • Zmp1's function involves degrading host- and bacterium-derived peptides.
  • Previous crystal structures of Zmp1 and related M13 metalloproteases were only in closed conformations, hindering understanding of substrate interactions.

Purpose of the Study:

  • To determine the open-state structures of Zmp1.
  • To elucidate the mechanisms of substrate binding and selectivity in M13 metalloproteases.
  • To provide insights for developing novel therapeutics against tuberculosis.

Main Methods:

  • Cryo-electron microscopy (cryo-EM) to obtain high-resolution structures.
  • Small-angle X-ray scattering (SAXS) to determine dominant solution states.
  • Structural analysis of conformational changes upon ligand binding.

Main Results:

  • Two open-state cryo-EM structures of Zmp1 were determined, representing dominant solution conformations.
  • Ligand binding was shown to induce conformational switches in four linker regions.
  • These switches drive rigid body motion of the D1 and D2 domains, opening the catalytic chamber.

Conclusions:

  • The open-state structures provide mechanistic insights into substrate binding and recognition for M13 metalloproteases.
  • Understanding Zmp1's conformational dynamics is key to its catalytic cycle.
  • These findings pave the way for future therapeutic strategies targeting Zmp1 in tuberculosis treatment.